Latest news with #NUPCO
Argaam
25-02-2025
- Business
- Argaam
Equipment House subsidiary receives favorable ruling, NUPCO ordered to pay SAR 61.2M
Scientific and Medical Equipment House Co. (Equipment House) stated that Riyadh Commercial Court affirmed the initial ruling issued in the lawsuit filed by its wholly-owned subsidiary, Protecta Visions Co. against National Unified Procurement Co. (NUPCO). In a filing to Tadawul, the court ordered NUPCO to pay SAR 60.57 million, as well as SAR 135,000 for expert fees, and SAR 500,000 for attorney's fees. The judgment was pronounced today, Feb. 25, and the company is awaiting the issuance of the judgement decree for execution. There is no change in the event-related costs, the company said, adding that there are no current costs associated with the event. In November 2024, Equipment House said the final enforceable appeal judgment issued in favor of Protecta Visions in the lawsuit against NUPCO was overturned, according to Argaam data. In October 2023, Equipment House obtained a certified and executed copy of the ruling issued by the Appellate Circuit of Riyadh Commercial Court in favor of Protecta Vision in the lawsuit against NUPCO. NUPCO was ordered to pay SAR 60.6 million to Protecta Visions, in addition to SAR 135,000 as expert fees and SAR 500,000 as legal fees.
Zawya
19-02-2025
- Health
- Zawya
Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiency
In a landmark moment for Saudi Arabia's healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under Vision 2030. The state-of-the-art facility, established through a collaboration between Sanofi, Sudair Pharma Company (SPC), and NUPCO, aims to enhance national drug security and improve access to life-saving insulin for millions of patients living with diabetes. The inauguration ceremony was attended by Bandar Al-Khorayef, Minister of Industry and Mineral Resources, alongside senior government officials, healthcare leaders, and industry partners. With diabetes affecting nearly 19% of Saudi Arabia's adult population, ensuring a stable and reliable supply of insulin has been a national priority. Historically reliant on imports, the Kingdom is now taking a transformative step toward localizing production to reduce supply chain vulnerabilities and provide more accessible treatment options. Preeti Futnani, MCO Lead and Specialty Care General Manager for Greater Gulf at Sanofi, underscored the company's long-standing commitment to Saudi Arabia and its role in supporting the nation's health transformation. 'Sanofi's journey in Saudi Arabia has always been about building something meaningful, and today, we take a major step forward,' Futnani stated. 'With this insulin manufacturing facility, we are not just producing medicine—we are investing in the country's future by ensuring a reliable supply of high-quality insulin, reducing dependency on imports, and empowering local talent to sustain this progress.' Once fully operational, the facility is expected to produce approximately 15 million insulin pens annually, covering the needs of 500,000 patients across Saudi Arabia. This production milestone will provide 70% of the insulin required by diabetic patients in the Kingdom, significantly enhancing national pharmaceutical security. Dr. Yasser AlObaida, Chief Executive Officer of Sudair Pharma Company, said: "At Sudir Pharma, we are pleased to collaborate with NUPCO and Sanofi in the establishment of this integrated facility. It will manufacture three types of insulin, including the latest biological insulin, which is widely used in diabetes treatment. The facility relies on the latest technologies throughout its manufacturing and packaging stages. The success of this initiative is driven by the unwavering support offered by all relevant authorities, including the Ministry of Health, the Ministry of Industry, and others, as well as the favorable policies and regulations in Saudi Arabia.' Beyond production, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills. This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical innovation. Sanofi, a global healthcare leader, has been present in Saudi Arabia for more than 50 years and has continuously invested in initiatives that support the country's healthcare goals. The localization of insulin production reflects the company's deep-rooted partnership with the Kingdom and its dedication to strongly contribute to Saudi Vision 2030. 'As our CEO Paul Hudson said during his participation in FII8 last year, 'The sky is the limit for future collaborations in the Kingdom for Sanofi,'' Futnani remarked. 'While today is a milestone, it is just the beginning. We are committed to working alongside Saudi Arabia in shaping the future of healthcare and leaving a lasting impact for generations to come.' The inauguration of the facility marks a pivotal step in Saudi Arabia's healthcare transformation, ensuring that patients have access to world-class treatment produced in Saudi, for Saudi, by Saudi. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (
Saudi Gazette
19-02-2025
- Health
- Saudi Gazette
Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiency
In a landmark moment for Saudi Arabia's healthcare sector, the Kingdom inaugurated its first local insulin manufacturing facility, a key milestone in advancing pharmaceutical self-sufficiency under Vision state-of-the-art facility, established through a collaboration between Sanofi, Sudair Pharma Company (SPC), and NUPCO, aims to enhance national drug security and improve access to life-saving insulin for millions of patients living with inauguration ceremony was attended by Bandar Al-Khorayef, Minister of Industry and Mineral Resources, alongside senior government officials, healthcare leaders, and industry diabetes affecting nearly 19% of Saudi Arabia's adult population, ensuring a stable and reliable supply of insulin has been a national priority. Historically reliant on imports, the Kingdom is now taking a transformative step toward localizing production to reduce supply chain vulnerabilities and provide more accessible treatment Futnani, MCO Lead and Specialty Care General Manager for Greater Gulf at Sanofi, underscored the company's long-standing commitment to Saudi Arabia and its role in supporting the nation's health transformation.'Sanofi's journey in Saudi Arabia has always been about building something meaningful, and today, we take a major step forward,' Futnani stated.'With this insulin manufacturing facility, we are not just producing medicine—we are investing in the country's future by ensuring a reliable supply of high-quality insulin, reducing dependency on imports, and empowering local talent to sustain this progress.'Once fully operational, the facility is expected to produce approximately 15 million insulin pens annually, covering the needs of 500,000 patients across Saudi Arabia. This production milestone will provide 70% of the insulin required by diabetic patients in the Kingdom, significantly enhancing national pharmaceutical Yasser AlObaida, Chief Executive Officer of Sudair Pharma Company, said: "At Sudir Pharma, we are pleased to collaborate with NUPCO and Sanofi in the establishment of this integrated facility. It will manufacture three types of insulin, including the latest biological insulin, which is widely used in diabetes treatment. The facility relies on the latest technologies throughout its manufacturing and packaging stages. The success of this initiative is driven by the unwavering support offered by all relevant authorities, including the Ministry of Health, the Ministry of Industry, and others, as well as the favorable policies and regulations in Saudi Arabia.'Beyond production, the facility is designed to support the Kingdom's ambition to develop a sustainable healthcare ecosystem by equipping local talent with specialized skills. This focus aligns with the broader objectives of the Health Sector Transformation Program, a key pillar of Vision 2030 aimed at improving healthcare accessibility and advancing medical a global healthcare leader, has been present in Saudi Arabia for more than 50 years and has continuously invested in initiatives that support the country's healthcare goals. The localization of insulin production reflects the company's deep-rooted partnership with the Kingdom and its dedication to strongly contribute to Saudi Vision 2030.'As our CEO Paul Hudson said during his participation in FII8 last year, 'The sky is the limit for future collaborations in the Kingdom for Sanofi,'' Futnani remarked. 'While today is a milestone, it is just the beginning. We are committed to working alongside Saudi Arabia in shaping the future of healthcare and leaving a lasting impact for generations to come.' The inauguration of the facility marks a pivotal step in Saudi Arabia's healthcare transformation, ensuring that patients have access to world-class treatment produced in Saudi, for Saudi, by Saudi.
Argaam
16-02-2025
- Business
- Argaam
NUPCO procurement exceeds SAR 25B annually: CCO
The size of National Unified Procurement Co.'s (NUPCO) purchases exceeds SAR 25 billion annually, said Chief Commercial Officer Khalid Al-Ghamdi, adding that the company is ready to keep pace with the expected expansion in the healthcare sector, which includes boosting hospital capacity and increasing the number of beds to 43,000 by 2030. In an interview with Argaam at the PIF Private Sector Forum, Al-Ghamdi indicated that the agreements signed by the company during the forum included three financial agreements with a total value of SAR 2.5 billion, including a deal worth SAR 500 million with Banque Saudi Fransi (BSF), FAB Bank KSA (SAR 1 billion) and Taameed Co. (SAR 1 billion). He further stated that these agreements aim to facilitate obtaining the necessary financing by suppliers, especially SMEs, to enhance their investments in the sector, and achieve greater flexibility in cash flows. NUPCO has an advanced infrastructure that includes seven main logistics centers with a storage capacity of up to 430,000 square meters. It seeks to develop its warehouses and introduce automated storage systems to improve the efficiency of distribution operations and ensure the availability of medicines and medical supplies by 100%, while reducing the time required for delivery and increasing accuracy in inventory management, according to the CCO. Al-Ghamdi also stated that the "Wasfaty" platform, managed by NUPCO, has contributed to facilitating patients' access to their medicines, as it currently serves more than 15 million patients and includes more than 5,500 pharmacies. NUPCO also signed an agreement with the "Foras" platform to support suppliers' access to investment opportunities, in addition to five agreements with logistics companies, including DHL, Aramex, Samsa and UPS, to improve distribution efficiency and ensure the delivery of medicines and medical supplies to all regions of the Kingdom, said the executive, noting that these partnerships help boost the company's ability to cover 97% of the regions of the Kingdom, while ensuring the speed and efficiency of delivery to hospitals and pharmacies. He added that NUPCO is studying opportunities for expansion outside Saudi Arabia in the future, especially in light of the Kingdom's preparations to host major events such as Expo 2030 and the 2034 World Cup.
Zawya
12-02-2025
- Health
- Zawya
Sanofi is transferring its global expertise in insulin production to Saudi Arabia
Saudi Arabia - As Saudi Arabia moves toward healthcare self-sufficiency under Vision 2030, the localization of vital pharmaceutical manufacturing has become a critical priority. In a major step forward, Sanofi, which signed last year an offtake agreement with Sudair Pharma Company (SPC) and NUPCO, is transferring its global expertise in insulin production to the Kingdom, ensuring a more resilient supply of high-quality treatment for diabetes patients. Lama Saleh, General Manager for General Medicines for Sanofi KSA & Gulf, said that, with a diabetes prevalence rate of 18.7%, (IDF Atlas 10th edition, IDF T1D index report) among the highest in the world, Saudi Arabia faces an urgent need to secure a stable and reliable supply of insulin. Historically reliant on imports, the Kingdom is now shifting toward localized production, a move that will significantly enhance national drug security and ensure greater access to life-saving treatment for hundreds of thousands of patients. Lama Saleh underscores the importance of this strategic partnership in strengthening healthcare resilience. Through the collaboration with Sudair Pharma and NUPCO, Sanofi is bringing its century-long expertise in diabetes care to Saudi Arabia, establishing with SPC a state-of-the-art insulin production facility that will manufacture, assemble, and package advanced SoloStar insulin pens within the Kingdom. Once fully operational, the facility will have the capacity to produce approximately 15 million insulin pens annually, meeting the treatment needs of 500,000 patients across Saudi Arabia. This production milestone is expected to cover 70% of diabetic patients receiving insulin in the Kingdom, significantly reducing dependency on external supply chains and bolstering pharmaceutical security. 'This initiative is about more than manufacturing; it's about ensuring that patients have consistent access to high-quality insulin, produced locally to meet their needs,' says Saleh. 'Through technology transfer, we are helping strengthen Saudi Arabia's healthcare infrastructure and contributing to a future where essential medicines are always within reach.' A Strategic Move Toward Vision 2030 The localization of insulin production aligns with the broader Health Sector Transformation Program, a key pillar of Vision 2030 that focuses on improving healthcare accessibility, advancing medical innovation, and strengthening national pharmaceutical capabilities. By developing high-tech manufacturing facilities and investing in specialized local talent, this initiative supports Saudi Arabia's goal of becoming a regional hub for biopharmaceutical production. For Sanofi, this investment goes beyond meeting immediate patient needs. It is also about building local expertise, transferring knowledge, and fostering innovation within the Kingdom. 'We are not just producing insulin. We are paving the way for the next generation of Saudi professionals, equipping them with the skills and expertise to lead in life sciences and biopharmaceuticals," Saleh explains. A Future of Healthcare Self-Sufficiency Saudi Arabia's efforts to localize pharmaceutical production are gaining momentum, and the insulin manufacturing is considered as a bold move and a key milestone in achieving national healthcare resilience. With greater production capacity, advanced technology transfer, and investment in local expertise, the Kingdom is implementing its strategy to long-term healthcare sustainability. For patients with diabetes, healthcare professionals, and the broader community, this shift marks a new era in Saudi Arabia's healthcare landscape—one where high-quality, locally produced medicines drive better health outcomes for all. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (
